Avances en inmunoterapia celular contra el melanoma maligno

An alternative strategy for cancer treatment is the manipulation of the immune system, denominated cancer immunotherapy. The immunotherapeutical use of cells of the immune system, like dendritic cells (DC), is being explored in different clinical protocols. Recently, we finalized a clinical phase I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	López,Mercedes, Escobar,Alejandro, Alfaro,Jorge, Fodor,Miguel, Larrondo,Milton, Ferrada,Carlos, Salazar-Onfray,Flavio
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2004
Materias:	Dendritic cells Immunotherapy Interleukin-2 Malignant melanoma
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000900014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872004000900014
record_format	dspace
spelling	oai:scielo:S0034-988720040009000142005-11-22Avances en inmunoterapia celular contra el melanoma malignoLópez,MercedesEscobar,AlejandroAlfaro,JorgeFodor,MiguelLarrondo,MiltonFerrada,CarlosSalazar-Onfray,Flavio Dendritic cells Immunotherapy Interleukin-2 Malignant melanoma An alternative strategy for cancer treatment is the manipulation of the immune system, denominated cancer immunotherapy. The immunotherapeutical use of cells of the immune system, like dendritic cells (DC), is being explored in different clinical protocols. Recently, we finalized a clinical phase I protocol, for the treatment of malignant melanoma, using DCs loaded with tumor lysates. Our results indicate that the subcutaneous application of DCs do not produce adverse effects. We also observed an increase of tumor spe-cific T lymphocytes precursors in the blood, associated to hypersensitivity reactions (DTH) in 60% of the treated patients. In most cases, an stability in the disease was observed, although without a significant association between vaccination and survival. Additionally, therapies based on Interleukin-2 (IL-2) have been used with relative success in the treatment of some kind of tumors since 1985. However, problems associated to the toxicity of IL-2 still restrict its massive use. Our direct experience with the use of IL-2, indicates that low doses and its subcutaneous application, maintains the beneficial effects for patients, eliminating the adverse effects. Based on the accumulated evidence during last the five years, we decided to implement an optimized clinical protocol, which alternatively combines dendritic cells vaccines with the use of low doses of IL-2 for the reinforcement of the immunological system (Rev Méd Chile 2004; 132: 1115-26)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.132 n.9 20042004-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000900014es10.4067/S0034-98872004000900014
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Dendritic cells Immunotherapy Interleukin-2 Malignant melanoma
spellingShingle	Dendritic cells Immunotherapy Interleukin-2 Malignant melanoma López,Mercedes Escobar,Alejandro Alfaro,Jorge Fodor,Miguel Larrondo,Milton Ferrada,Carlos Salazar-Onfray,Flavio Avances en inmunoterapia celular contra el melanoma maligno
description	An alternative strategy for cancer treatment is the manipulation of the immune system, denominated cancer immunotherapy. The immunotherapeutical use of cells of the immune system, like dendritic cells (DC), is being explored in different clinical protocols. Recently, we finalized a clinical phase I protocol, for the treatment of malignant melanoma, using DCs loaded with tumor lysates. Our results indicate that the subcutaneous application of DCs do not produce adverse effects. We also observed an increase of tumor spe-cific T lymphocytes precursors in the blood, associated to hypersensitivity reactions (DTH) in 60% of the treated patients. In most cases, an stability in the disease was observed, although without a significant association between vaccination and survival. Additionally, therapies based on Interleukin-2 (IL-2) have been used with relative success in the treatment of some kind of tumors since 1985. However, problems associated to the toxicity of IL-2 still restrict its massive use. Our direct experience with the use of IL-2, indicates that low doses and its subcutaneous application, maintains the beneficial effects for patients, eliminating the adverse effects. Based on the accumulated evidence during last the five years, we decided to implement an optimized clinical protocol, which alternatively combines dendritic cells vaccines with the use of low doses of IL-2 for the reinforcement of the immunological system (Rev Méd Chile 2004; 132: 1115-26)
author	López,Mercedes Escobar,Alejandro Alfaro,Jorge Fodor,Miguel Larrondo,Milton Ferrada,Carlos Salazar-Onfray,Flavio
author_facet	López,Mercedes Escobar,Alejandro Alfaro,Jorge Fodor,Miguel Larrondo,Milton Ferrada,Carlos Salazar-Onfray,Flavio
author_sort	López,Mercedes
title	Avances en inmunoterapia celular contra el melanoma maligno
title_short	Avances en inmunoterapia celular contra el melanoma maligno
title_full	Avances en inmunoterapia celular contra el melanoma maligno
title_fullStr	Avances en inmunoterapia celular contra el melanoma maligno
title_full_unstemmed	Avances en inmunoterapia celular contra el melanoma maligno
title_sort	avances en inmunoterapia celular contra el melanoma maligno
publisher	Sociedad Médica de Santiago
publishDate	2004
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000900014
work_keys_str_mv	AT lopezmercedes avanceseninmunoterapiacelularcontraelmelanomamaligno AT escobaralejandro avanceseninmunoterapiacelularcontraelmelanomamaligno AT alfarojorge avanceseninmunoterapiacelularcontraelmelanomamaligno AT fodormiguel avanceseninmunoterapiacelularcontraelmelanomamaligno AT larrondomilton avanceseninmunoterapiacelularcontraelmelanomamaligno AT ferradacarlos avanceseninmunoterapiacelularcontraelmelanomamaligno AT salazaronfrayflavio avanceseninmunoterapiacelularcontraelmelanomamaligno
_version_	1718436169101869056

Avances en inmunoterapia celular contra el melanoma maligno

Ejemplares similares